Back to Search Start Over

Comprehensive geriatric assessment guided radiotherapy in elderly patients with locally advanced rectal cancer—exploratory results on nonoperative cohort of a multicenter prospective study

Authors :
Yue-Xin Yang
Yuan Tang
Ning Li
Yu Tang
Yun-Jie Cheng
Lin Yang
Hui Fang
Ning-Ning Lu
Shu-Nan Qi
Bo Chen
Shu-Lian Wang
Yong-Wen Song
Yue-Ping Liu
Ye-Xiong Li
Zheng Liu
Jian-Wei Liang
Hai-Zeng Zhang
Hai-Tao Zhou
Jun Wang
Wen-Yang Liu
Jing Jin
Source :
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Publication Year :
2024
Publisher :
SAGE Publishing, 2024.

Abstract

Background: Chemoradiotherapy (CRT) is the main treatment for elderly patients with non-metastatic rectal cancer who are ineligible for or decline surgery, but the optimal modality remains unclear. Objectives: This study was to validate the safety and efficacy of comprehensive geriatric assessment (CGA) guided radiotherapy in older patients. Design: An exploratory analysis of a single-arm, multicenter, Phase II trial. Methods: Patients aged over 70 and diagnosed with rectal cancer were enrolled and evaluated by CGA. CGA-guided radiotherapy was individually conducted in a multidisciplinary setting. Patients in fit, intermediate, and frail groups were scheduled to receive CRT, long-course radiotherapy, and short-course radiotherapy (SCRT) alone respectively. Patients who were unfit for or refused surgery were analyzed for acute toxicities and survival outcomes. Results: In a total of 109 enrolled patients, 47 individuals who did not undergo surgery were included, with 26, 9, and 12 categorized into fit, intermediate, and frail groups. Only 11 (23.4%) grade 3 or above toxicities were observed overall. Within a median follow-up of 69.0 months, the 3-year overall survival (OS), progression-free survival (PFS), and cancer-specific survival (CSS) rates were 44.3% (95% CI: 32.1%–61.2%), 25.5% (95% CI: 15.7%–41.6%) and 61.0% (95% CI: 47.8%–77.6%) in total. The 5-year OS, PFS, and CSS reached 15.0% (95% CI: 7.4%–30.3%), 14.6% (95% CI: 7.3%–29.4%), and 36.2% (95% CI: 22.0%–59.4%), with no significant difference among the three subgroups. SCRT ( p

Details

Language :
English
ISSN :
17588359
Volume :
16
Database :
Directory of Open Access Journals
Journal :
Therapeutic Advances in Medical Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.3eeae12176f0479490226a29fcae287f
Document Type :
article
Full Text :
https://doi.org/10.1177/17588359241296386